KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814
13 janv. 2020 07h00 HE
|
KaNDy Therapeutics
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814 ~Phase 2b dose range finding study showed rapid and highly significant...
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814
13 janv. 2020 02h00 HE
|
KaNDy Therapeutics
KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814 ~Phase 2b dose range finding study showed rapid and highly significant...
KaNDy Therapeutics announces the appointment of Andrew Kay as Independent Chairman of the Board
07 janv. 2019 07h00 HE
|
KaNDy Therapeutics
KaNDy Therapeutics announces the appointment of Andrew Kay as Independent Chairman of the Board Stevenage, UK, 7 January 2018 - KaNDy Therapeutics, a clinical-stage company developing a potential...
KaNDy Therapeutics announces the appointment of Andrew Kay as Independent Chairman of the Board
07 janv. 2019 02h00 HE
|
KaNDy Therapeutics
KaNDy Therapeutics announces the appointment of Andrew Kay as Independent Chairman of the Board Stevenage, UK, 7 January 2018 - KaNDy Therapeutics, a clinical-stage company developing a potential...
KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms
11 déc. 2018 07h00 HE
|
KaNDy Therapeutics
KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms Stevenage, UK, 11 December 2018 - KaNDy Therapeutics, a clinical-stage...
KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms
11 déc. 2018 02h00 HE
|
KaNDy Therapeutics
KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms Stevenage, UK, 11 December 2018 - KaNDy Therapeutics, a clinical-stage...